Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

896.53 +33.67 (+3.90%)
Official Closing Price Updated: 4:10 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Hims & Hers Health (HIMS) Surges After Hours on Robust Q3 and Renewed Novo Nordisk (NVO) Wegovy Talks
Hims & Hers Health (NYSE: HIMS) became a significant after-hours mover on Monday, November 3, 2025, following the release of its third-quarter 2025 financial results and the pivotal announcement of... 
Via MarketMinute
Topics Artificial Intelligence Economy
Stay informed with the top movers within the S&P500 index on Monday.
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday. 
Via Chartmill
What's Up With The Rise In Eli Lilly Stock Today?
Eli Lilly shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
ELI LILLY & CO (NYSE:LLY): A Dividend Growth Stock with Strong Profitability
Discover Eli Lilly (LLY), a dividend stock with a 10+ year payment history, 15.59% average growth, strong profitability, and solid financial health for reliable income. 
Via Chartmill
2 Healthcare Stocks for Individual Investors With a 30-Year Time Horizon
The healthcare industry is chock-full of opportunities for long-term investors. 
Via The Motley Fool
Topics Government World Trade
2 Beaten-Down Stocks That Could Be About to Rally
It would be best to get in before the rest of the market pounces on these opportunities. 
Via The Motley Fool
Prediction: The Next Eli Lilly Might Already Be Trading Under $50
Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left. 
Via The Motley Fool
What To Expect From Zoetis’s (ZTS) Q3 Earnings
Animal health company Zoetis (NYSE:ZTS) will be reporting results this Tuesday morning. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
Corcept Earnings: What To Look For From CORT
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be reporting results this Tuesday after market close. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
Pfizer (PFE) Q3 Earnings: What To Expect
Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Supernus Pharmaceuticals (SUPN) Reports Q3: Everything You Need To Know Ahead Of Earnings
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting earnings this Tuesday after market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Rethinking Your Portfolio: The Stocks That Could Outperform for Years
Now is a great time to be shopping for stocks that can anchor your portfolio. 
Via The Motley Fool
Topics Bonds Retirement
Should You Buy Viking Therapeutics Before Nov. 5?
Viking's stock surged in one trading session after a positive clinical trial report last year. 
Via The Motley Fool
Should You Buy the Vanguard S&P 500 ETF With the Stock Market at All-Time Highs? History Offers a Clear Answer
Powerful themes like artificial intelligence (AI) continue to drive the S&P 500 to new highs. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio
The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
S&P 500 Giants JPMorgan, Eli Lilly Lead Five Stocks Near Buy Points
Four are already actionable, with the holdout just below a possible breakout. 
Via Investor's Business Daily
Topics Stocks
Why Bio-Techne (TECH) Stock Is Up Today
Shares of life sciences company Bio-Techne (NASDAQ:TECH) jumped 2.8% in the afternoon session after Baird adjusted its price target on the company, signaling a more positive outlook. The investment... 
Via StockStory
Topics Artificial Intelligence Supply Chain World Trade
Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say
Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on strong obesity drug momentum. 
Via Benzinga
AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of... 
Via TokenRing AI
Topics Artificial Intelligence Supply Chain
AI Revolutionizes Pharma R&D: A New Era of Accelerated Drug Discovery and Personalized Medicine
Artificial intelligence (AI) is ushering in a transformative era for pharmaceutical research and development (R&D), fundamentally reshaping how new medicines are discovered, developed, and brought to... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
Why iRhythm (IRTC) Stock Is Trading Up Today
Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) jumped 3.2% in the afternoon session after it reported strong third-quarter financial results that surpassed expectations and... 
Via StockStory
Topics Artificial Intelligence World Trade
Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)
Novartis is set to boost its developmental pipeline with this acquisition. 
Via The Motley Fool
Meta Meltdown Sends Nasdaq Tumbling as Apple Shines After Hours
Wall Street slipped on Thursday as disappointing results from Meta and cautious tones from the Fed weighed on sentiment. But after the closing bell, Apple’s record-breaking numbers helped restore a bit... 
Via Chartmill
Topics Economy
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise
Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism. 
Via Stocktwits
1 Healthcare Stock with Impressive Fundamentals and 2 We Ignore
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Twilio Stock Rises On Q3 Earnings Beat, Raised Guidance
Twilio stock rose after the software maker reported Q3 earnings that topped estimates and hiked its full-year revenue outlook. 
Via Investor's Business Daily
Topics Artificial Intelligence Earnings
Cloudflare Earnings Top Estimates. Revenue Outlook Above Views.
Cloudflare stock wavered after the company reported Q3 earnings that topped estimates and guidance came in slightly above views. 
Via Investor's Business Daily
Topics Artificial Intelligence
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush. 
Via Benzinga
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.